Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:820-826
Published online before print February 21, 2008, doi: 10.1161/ATVBAHA.107.156281
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Additional Materials
Right arrow All Versions of this Article:
28/5/820    most recent
ATVBAHA.107.156281v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cyrus, T.
Right arrow Articles by Lanza, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cyrus, T.
Right arrow Articles by Lanza, G. M.
Related Collections
Right arrowRelated Article
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:820.)
© 2008 American Heart Association, Inc.

Integrated Physiology/Experimental Medicine

Intramural Delivery of Rapamycin With {alpha}vβ3-Targeted Paramagnetic Nanoparticles Inhibits Stenosis After Balloon Injury

Tillmann Cyrus; Huiying Zhang; John S. Allen; Todd A. Williams; Grace Hu; Shelton D. Caruthers; Samuel A. Wickline; Gregory M. Lanza

From the Division of Cardiology (T.C., H.Z., J.S.A., T.A.W., G.H., S.A.W., G.M.L.), Washington University School of Medicine, Saint Louis, Mo; and Philips Medical Systems (S.D.C.), Andover, Mass.

Correspondence to Tillmann Cyrus, MB, MD, Washington University School of Medicine, 4320 Forest Park Avenue, Suite 101, Campus Box 8215, Saint Louis, MO 63108. E-mail tcyrus{at}im.wustl.edu

Background— Drug eluting stents prevent vascular restenosis but can delay endothelial healing. A rabbit femoral artery model of stenosis formation after vascular injury was used to study the effect of intramural delivery of {alpha}vβ3-integrin-targeted rapamycin nanoparticles on vascular stenosis and endothelial healing responses.

Methods and Results— Femoral arteries of 48 atherosclerotic rabbits underwent balloon stretch injury and were locally treated with either (1) {alpha}vβ3-targeted rapamycin nanoparticles, (2) {alpha}vβ3-targeted nanoparticles without rapamycin, (3) nontargeted rapamycin nanoparticles, or (4) saline. Intramural binding of integrin-targeted paramagnetic nanoparticles was confirmed with MR molecular imaging (1.5 T). MR angiograms were indistinguishable between targeted and control arteries at baseline, but 2 weeks later they showed qualitatively less luminal plaque in the targeted rapamycin treated segments compared with contralateral control vessels. In a first cohort of 19 animals (38 vessel segments), microscopic morphometric analysis of the rapamycin-treated segments revealed a 52% decrease in the neointima/media ratio (P<0.05) compared to control. No differences (P>0.05) were observed among balloon injured vessel segments treated with {alpha}vβ3-targeted nanoparticles without rapamycin, nontargeted nanoparticles with rapamycin, or saline. In a second cohort of 29 animals, endothelial healing followed a parallel pattern over 4 weeks in the vessels treated with {alpha}vβ3-targeted rapamycin nanoparticles and the 3 control groups.

Conclusions— Local intramural delivery of {alpha}vβ3-targeted rapamycin nanoparticles inhibited stenosis without delaying endothelial healing after balloon injury.

Femoral arteries of 48 atherosclerotic rabbits underwent balloon stretch injury and were treated locally with either: (1) {alpha}vβ3-targeted rapamycin nanoparticles, (2) {alpha}vβ3-targeted nanoparticles without rapamycin, (3) nontargeted rapamycin nanoparticles, or (4) saline. Intramural delivery of {alpha}vβ3-targeted rapamycin nanoparticles inhibited stenosis at 2 weeks without delaying endothelial healing following balloon injury over 4 weeks.


Key Words: nanoparticles • MRI • restenosis • rapamycin • drug delivery


Related Article:

Nanomedicine Captures Cardiovascular Disease
Willem J.M. Mulder and Zahi A. Fayad
Arterioscler Thromb Vasc Biol 2008 28: 801-802. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
S.-L. Huang, P. H. Kee, H. Kim, M. R. Moody, S. M. Chrzanowski, R. C. MacDonald, and D. D. McPherson
Nitric oxide-loaded echogenic liposomes for nitric oxide delivery and inhibition of intimal hyperplasia.
J. Am. Coll. Cardiol., August 11, 2009; 54(7): 652 - 659.
[Abstract] [Full Text] [PDF]

Home page
 Circ Cardiovasc ImagingHome page
M. Nahrendorf, D. E. Sosnovik, B. A. French, F. K. Swirski, F. Bengel, M. M. Sadeghi, J. R. Lindner, J. C. Wu, D. L. Kraitchman, Z. A. Fayad, et al.
Multimodality Cardiovascular Molecular Imaging, Part II
Circ Cardiovasc Imaging, January 1, 2009; 2(1): 56 - 70.
[Full Text] [PDF]

Home page
 Circ Cardiovasc IntervHome page
M. K. Reddy, J. K. Vasir, S. K. Sahoo, T. K. Jain, M. M. Yallapu, and V. Labhasetwar
Inhibition of Apoptosis Through Localized Delivery of Rapamycin-Loaded Nanoparticles Prevented Neointimal Hyperplasia and Reendothelialized Injured Artery
Circ Cardiovasc Interv, December 1, 2008; 1(3): 209 - 216.
[Abstract] [Full Text] [PDF]


ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.